Product custom-nanocomposites-nanopeptides

Home > products > custom-nanocomposites> nanopeptides

Catalog	name	Description	price
R-Mcs-515	Cy5-KTP@PLGA-PEG Loading peptides,±150nm	Cy5-KTP@PLGA-PEG Loading peptides,± 150nm, are suitable for targeted delivery studies guided by in vivo imaging. This system consists of hydrophobic PLGA as the core and hydrophilic PEG as the shell, forming stable core-shell structured nanomicelles that can efficiently encapsulate hydrophobic or amphiphilic peptides and achieve functionalization through surface modification.	price>
R-Mcs-516	RVG29 modified liposomes@Nattokinase	Liposomal loaded Nattokinase modified with RVG29 is a cutting-edge brain targeted nanodelivery system aimed at efficiently delivering thrombolytic enzymes through the blood-brain barrier (BBB) for the prevention or adjuvant treatment of ischemic stroke, cerebral microthrombi, and related neurodegenerative diseases.	price>
R-Mcs-517	Nintedanib and Dexamethasone@Liposomal CY5.5,100-150nm	Nintedanib and Dexamethasone@Liposomal CY5.5,100-150nm/Liposome@with Nintedanib and Dexamethasone modified CY5.5 is a multifunctional targeted nano delivery system that achieves synergistic anti fibrotic and anti-inflammatory effects through liposome encapsulated dual drugs, and uses CY5.5 near-infrared fluorescence labeling to achieve real-time visualization tracking of in vivo distribution. It is mainly used for the study of acute exacerbation of pulmonary fibrosis (AE-IPF) or tumor related fibrosis microenvironment.	price>
R-M1-cs8806	RVG29 modified liposomes loaded with paclitaxel	The RVG29 modification on the liposomes provides a targeted approach to deliver paclitaxel specifically to neuronal cells, potentially for the treatment of neurological disorders or brain tumors. The RVG29 peptide interacts with nAChR on neuronal cells, promoting the endocytosis of the liposomes and subsequent release of the paclitaxel within the targeted cells.RVG29 modified liposomes loaded with paclitaxel offer the benefit of targeted drug delivery to neuronal cells, improving the efficacy and selectivity of paclitaxel treatment.RVG29 is a peptide derived from the rabies virus glycoprotein, which has a high affinity for the neuronal acetylcholine receptor (nAChR), specifically present on neuronal cells. By modifying liposomes with RVG29, they can be targeted specifically to neuronal cells, allowing for enhanced drug delivery to these cells.	price>
R-M1-cs8807	Liposome loaded tectorigenin,surface modified peptide APWHLSSQYSRT	The combination of liposome loaded tectorigenin and surface-modified peptide APWHLSSQYSRT refers to the preparation of liposomes that encapsulate tectorigenin, a natural compound, while the surface of the liposomes is modified with the peptide sequence APWHLSSQYSRT. Surface modification of liposomes with peptides, such as APWHLSSQYSRT, offers a way to enhance drug delivery and target specific cells or tissues. The sequence of the peptide may have been specifically designed to interact with a receptor or biomarker present on the surface of target cells.	price>
R-M1-cs8810	SS31 peptide/simvastatin @ ROS responsive liposome	By encapsulating SS31 peptide and simvastatin within ROS-responsive liposomes, it may be possible to achieve targeted delivery of both compounds to areas of high ROS levels, such as in certain disease states. The ROS-responsive liposomes are designed to release the encapsulated SS31 peptide and simvastatin in response to the presence of ROS, allowing for localized therapeutic effects and potentially enhanced efficacy. This combination could be explored in various biomedical applications, including the treatment of oxidative stress-related disorders or conditions where ROS plays a significant role, such as cardiovascular diseases, neurodegenerative disorders, or inflammation-associated conditions.	price>
R-M1-8887	Fluvoxamine@LNP-TFR (sequence:THRPPMWSPVWP) 100nm	The Fluvoxamine@Liposome nanoparticles-TFR (sequence: THRPPMWSPVWP) involves the targeted delivery of the therapeutic drug fluvoxamine using liposome nanoparticles functionalized with a peptide sequence that targets transferrin receptors. This type of drug delivery system has the potential to enhance the specificity and efficiency of drug delivery to particular cells or tissues in the body.	price>
R-M2-9507	S2P(CRTLTVRKC)-PLGA-Maleimide-PEG2k nanoparticles containing Imatinib	S2P peptide-conjugated PLGA-Maleimide-PEG nanoparticles/S2P(CRTLTVRKC)-PLGA-Maleimide-PEG2k nanoparticles containing Imatinib containing Imatinib for targeting drug delivery to atherosclerotic plaques.Stabilin-2 peptide with sequence of CRTLTVRKC is a specific ligand to stabilin-2,so it was synthesized for using as the targeting agent for atherosclerosis.	price>
R-M2-9509	S2P Peptide-PLGA-Maleimide-PEG nanoparticles	S2P peptide-PLGA-Maleimide-PEG nanoparticles/CRTLTVRKC-PLGA-Maleimide-PEG nanoparticles/S2P Peptide(CRTLTVRKC)-PLGA-Maleimide-PEG nanoparticles is a promising approach to targeted drug delivery. Targeting specific types of cancer cells using S2P peptides while delivering chemotherapeutics or RNA-based therapeutics.The system may be explored for delivering nucleic acids (DNA or RNA) for gene therapy applications, with the peptide aiding in cellular uptake.Utilizing this platform for delivering antigens or immune modulators to enhance immune response against tumors.	price>
R-M2-9510	CRTLTVRKC-PLGA-PEG nanoparticles containing imatinib	S2P Peptide-PLGA-PEG nanoparticles containing imatinib/S2P peptide (CRTLTVRKC) conjugated to PLGA-PEG nanoparticles is a sophisticated compound designed for improved delivery of imatinib. This approach aims to enhance the therapeutic efficacy of imatinib, a targeted treatment used primarily for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs), while minimizing side effects through more effective targeting and controlled release.The nanoparticles can be engineered to also deliver other chemotherapy agents or to administer alongside imatinib to create combination therapies that enhance anti-tumor efficacy.The S2P peptide facilitates targeting specific cancer cells, potentially improving the therapeutic index of imatinib by concentrating the drug where it is most needed.The PLGA matrix allows for controlled release, promoting a prolonged therapeutic effect and minimizing the peaks and troughs associated with traditional dosing regimens.By targeting cancer cells specifically, the risk of side effects associated with systemic drug exposure can be reduced.The PEGylation process enhances the solubility and stability of the nanoparticles, improving bioavailability.	price>

...